Vertex, Inc. (NASDAQ:VERX), a provider of cloud-based tax solutions with a market capitalization of $4.2 billion, finds itself at a crossroads as it navigates through a challenging fiscal landscape.

Vertex Pharmaceuticals reported pivotal pediatric data for CASGEVY for young children with severe sickle cell disease and ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biopharmaceutical company with a market capitalization of over $100 billion specializing in cystic fibrosis (CF) treatments and expanding into other ...

Stock performance snapshot Vertex Pharmaceuticals (VRTX) is drawing investor attention after recent trading left the stock ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals’ drug, Trikafta, which was approved as a breakthrough treatment for cystic fibrosis last year, needs to be 73 percent cheaper to be cost-effective, an analysis found. The ...

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - For the primary ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a prominent player in the biotechnology industry with a market capitalization of $117 billion, is navigating a pivotal phase in its growth strategy. As the ...